Transcend Capital Advisors LLC Buys 281 Shares of Sanofi (NASDAQ:SNY)

Transcend Capital Advisors LLC grew its holdings in Sanofi (NASDAQ:SNY) by 5.3% during the 4th quarter, Holdings Channel reports. The fund owned 5,623 shares of the company’s stock after buying an additional 281 shares during the period. Transcend Capital Advisors LLC’s holdings in Sanofi were worth $271,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. Waterfront Wealth Inc. raised its position in Sanofi by 46.0% in the fourth quarter. Waterfront Wealth Inc. now owns 49,958 shares of the company’s stock worth $2,409,000 after acquiring an additional 15,748 shares during the period. Concurrent Investment Advisors LLC raised its position in Sanofi by 2.6% in the fourth quarter. Concurrent Investment Advisors LLC now owns 37,946 shares of the company’s stock worth $1,830,000 after acquiring an additional 973 shares during the period. Ieq Capital LLC raised its position in Sanofi by 14.1% in the fourth quarter. Ieq Capital LLC now owns 9,520 shares of the company’s stock worth $459,000 after acquiring an additional 1,175 shares during the period. Private Advisor Group LLC raised its position in Sanofi by 6.1% in the fourth quarter. Private Advisor Group LLC now owns 55,551 shares of the company’s stock worth $2,679,000 after acquiring an additional 3,213 shares during the period. Finally, Hara Capital LLC raised its position in Sanofi by 16.2% in the fourth quarter. Hara Capital LLC now owns 4,888 shares of the company’s stock worth $236,000 after acquiring an additional 680 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

SNY has been the topic of several recent research reports. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $54.46 on Monday. The firm has a fifty day moving average price of $50.95 and a 200-day moving average price of $52.53. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The stock has a market cap of $138.21 billion, a PE ratio of 21.87, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.